These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22384240)

  • 1. Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.
    Kumar AA; Palamaner Subash Shantha G; Kahan S; Samson RJ; Boddu ND; Cheskin LJ
    PLoS One; 2012; 7(2):e32395. PubMed ID: 22384240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride/HDL ratio as a screening tool for predicting success at reducing anti-diabetic medications following weight loss.
    Palamaner Subash Shantha G; Kumar AA; Kahan S; Irukulla PK; Cheskin LJ
    PLoS One; 2013; 8(7):e69285. PubMed ID: 23869240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study.
    Shantha GP; Kumar AA; Kahan S; Cheskin LJ
    Diabetes Educ; 2012; 38(3):417-26. PubMed ID: 22508341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.
    Johnson M; Krosnick A; Carson P; McDade AM; Laraway K
    Clin Ther; 1998; 20(4):691-8. PubMed ID: 9737829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA
    Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics.
    Chen JF; Chang CM; Kuo MC; Tung SC; Tsao CF; Tsai CJ
    Diabetes Res Clin Pract; 2016 Oct; 120():8-14. PubMed ID: 27498072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical score to predict dose reductions of antidiabetes medications with intentional weight loss: A retrospective cohort study.
    Shantha GP; Kumar AA; Ravi V; Khanna RC; Kahan S; Cheskin LJ
    Biomed J; 2016 Jun; 39(3):188-94. PubMed ID: 27621120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
    Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
    Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study.
    Aldekhail NM; Morrison DS; Khojah H; Sloan B; McLoone P; MacNaughton S; Shearer R; Logue J
    Diabet Med; 2020 Feb; 37(2):248-255. PubMed ID: 31365143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
    Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
    Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
    Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
    Horton ES; Silberman C; Davis KL; Berria R
    Diabetes Care; 2010 Aug; 33(8):1759-65. PubMed ID: 20460445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
    Deol H; Lekkakou L; Viswanath AK; Pappachan JM
    Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.